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barrestins are molecular scaffolds that can bring together three-component mitogen-activated
protein kinase signalling modules to promote signal compartmentalisation. We use peptide array
technology to deﬁne novel interfaces between components within the c-Jun N-terminal kinase
(JNK)/barrestin signalling complex. We show that barrestin 1 and barrestin 2 associate with JNK3
via the kinase N-terminal domain in a region that, surprisingly, does not harbour a known ‘common
docking’ motif. In the N-domain and C-terminus of barrestin 1 and barrestin 2 we identify two novel
apoptosis signal-regulating kinase 1 binding sites and in the N-domain of the barrestin 1 and
barrestin 2 we identify a novel MKK4 docking site.
Structured summary:
MINT-7263196, MINT-7263175: Arrestin beta-2 (uniprotkb:P32121) binds (MI:0407) to ASK1 (uni-
protkb:Q99683) by peptide array (MI:0081)
MINT-7263136: JNK3 (uniprotkb:P53779) binds (MI:0407) to Arrestin beta-1 (uniprotkb:P49407) by pep-
tide array (MI:0081)
MINT-7263161: JNK3 (uniprotkb:P53779) binds (MI:0407) to Arrestin beta-2 (uniprotkb:P32121) by pep-
tide array (MI:0081)
MINT-7263304: Arrestin beta-1 (uniprotkb:P49407) physically interacts (MI:0915) with ASK1 (uni-
protkb:Q99683) by anti tag coimmunoprecipitation (MI:0007)
MINT-7263286: Arrestin beta-2 (uniprotkb:P32121) binds (MI:0407) toMKK4 (uniprotkb:P45985) by pep-
tide array (MI:0081)
MINT-7263231, MINT-7263254: Arrestin beta-1 (uniprotkb:P49407) binds (MI:0407) to ASK1 (uni-
protkb:Q99683) by peptide array (MI:0081)
MINT-7263269: Arrestin beta-1 (uniprotkb:P49407) binds (MI:0407) toMKK4 (uniprotkb:P45985) by pep-
tide array (MI:0081)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction phosphorylating a large number of target proteins, which includeMitogen-activated protein kinase (MAPK) signalling cascades of
the ERK (extracellular-signal regulated kinase), p38 and JNK path-
ways (c-Jun N-terminal kinase) are activated via cell surface recep-
tors in response to a variety of physical and chemical stimuli [1]. In
each case, signals are relayed in a three-kinase sequence, going from
MAPK kinase kinase throughMAPKkinase toMAPK. ActivatedMAP-
Ks have the ability to elicit a myriad of cellular responses bychemical Societies. Published by E
minal kinase; ASK1, apoptosis
site, common docking site
).other kinases, enzymes and transcription factors. Each individual
MAPK cascade is activated by a unique set of stimuli, though it is
also known that distinct MAPKmodules can be triggered in parallel
by a common initiating event [2]. Despite the plethora of possible
stimuli and small number of MAPK signalling cascades, the MAPK
signalling networks are known to operate in a highly regulated
manner with speciﬁcity of action being maintained by a family of
unconnected scaffold proteins [3]. Such signalling scaffold proteins
act to bring the components of each pathway together, allowing
physical association of pathway members to promote rapid trans-
mission of the signal coupledwith spatial sequestration, which con-
fers compartmentalisation upon signal output [4].lsevier B.V. All rights reserved.
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known to sequester the three tier kinase modules from the ERK,
p38 and JNK signalling cascades [5]. JNK3 was originally shown
to associate with barrestin in a yeast two-hybrid screen with fur-
ther experimentation showing that barrestin could scaffold not
only the MAPK, JNK but also the MAPK kinase, MAPK kinase 4
(MKK4) and the MAPK kinase kinase, ASK1 (apoptosis signal-regu-
lating kinase 1) [6,7]. More recent studies into the mechanism of
assembly of MAPK modules by barrestins have suggested that all
four mammalian isoforms of barrestin are able to bind the three
components of the JNK module (JNK, MKK4 and ASK1) with com-
parable afﬁnity and that all of these kinases associate with both
the N- and C-domains of the barrestin proteins [8,9]. Traditionally,
analyses to determine interaction sites are both time-consuming
and expensive, involving truncation, domain swapping and site-
speciﬁc mutagenesis studies. Truncation approaches together with
a limited number of mutagenesis analyses have been used to
roughly deﬁne the molecular interaction sites within the barres-
tin/JNK module complex [6,8–11]. Use of such approaches has,
however, yielded little information about key sites involved in
the formation of the barrestin/JNK complex and hence there is a
paucity of information on the residues involved.
Recently, peptide array technology has proved to be a novel,
rapid and powerful tool for studying protein–protein interactions
in a number of systems (see e.g. [12,13]) and has been veriﬁed
for the deﬁnition of optimal docking sequence motifs with mem-
bers of MAPK cascades [14]. The technique has also been utilised
to accurately predict the binding sites on barrestin for a number
of interacting partners including PDE4D5 [15], ERK [16] and MEK
[17]. Here we have employed this technique to further delineate
the binding site for barrestin on JNK and to uncover potential sites
that allow barrestin to scaffold both ASK1 and MKK4.2. Materials and methods
Peptide libraries were produced by automatic SPOT synthesis
and synthesised on continuous cellulose membrane supports on
Whatman 50 cellulose membranes using Fmoc-chemistry with
the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments
AG, Köln, Germany) as previously described [18]. The interaction
of spot-immobilised peptides with puriﬁed, recombinant GST and
barrestin 1–GST, barrestin 2–GST fusion proteins, MKK4 and ASK1
was determined by overlaying the cellulose membranes with
10 lg/ml protein as previously described [19]. The puriﬁcation of
GST, barrestin 1–GST and barrestin 2–GST were as previously de-
scribed [19]. Pure MKK4 (codes 14–377) and active ASK1–GST
(codes 14–606) and antibodies against MKK4 (04-382) were pur-
chased fromUpstate (Millipore), UK. Anti-GSTmonoclonal antibody
(SC-53909) was purchased from Santa Cruz. Densitometric analysis
was done using Quantity One software (Biorad). The immunopre-
cipitation of FLAG-barrestin 1 and subsequent blotting for the asso-
ciation of ASK1 was done as previously described for MEK1 [17].3. Results
3.1. Elucidation of barrestin-binding site on JNK3
In this study, we used peptide array analysis to probe various
interactions within the JNK/barrestin system. To do this we
exploited peptide array technology to synthesise libraries of over-
lapping 25-mer peptides, each shifted by ﬁve amino acids, span-
ning the complete sequence of JNK3, barrestin 1 and barrestin 2.
Recent studies investigating the association of the ASK1–MKK4–
JNK3 module with barrestins have indicated that the N-terminus
of JNK3 harbours the site of association with barrestins and thatboth barrestin 1 and barrestin 2 appear to bind JNK3 with similar
ability [8,11]. In agreement with such ﬁndings, puriﬁed barrestin
1–GST and barrestin 2–GST, but not GST, bound similarly to 25-
mer peptides representing a full length JNK3 peptide array
(Fig. 1A), identifying an interaction site within the JNK3 N-terminal
region that spanned amino acids 6–45. In order to deﬁne further
the amino acids that potentially allow binding of JNK3 to barrestin
1 and barrestin 2, we screened a family of 22-mer peptides whose
sequence contained L3–F24 of JNK3. The 22 progeny of this peptide
each contained a sequential single substitution of alanine for suc-
cessive amino acids to form an alanine-scanning array that was
once again probed with barrestin 1 and barrestin 2–GST. When this
region was subjected to such binding analysis, it became apparent
that barrestin 1 and barrestin 2–GST binding proﬁles were similar.
Notably, alanine substitution of F5 compromised barrestin 1 and
barrestin 2 binding (Fig. 1B) and the run of residues between P12
and G23, save D15 and A19, more speciﬁcally, compromised barres-
tin 2 binding (Fig. 1B). Gratifyingly, such a result is in agreement
with previous truncation and site-directed mutagenesis studies
[11], which have shown the JNK N-terminal and, in particular, ami-
no acids between C9 and I18 to be important for the association of
barrestin. However, our approach extends appreciation of the
interaction surface on JNK, in that residues F5 and C21–F24 also ap-
pear have a role to play in the context of barrestin 1 and barrestin
2/JNK interaction, while D15 likely is unimportant.
3.2. ASK1 binds to N- and C-domains of barrestin 1 and barrestin 2
To discover elements within ASK1 and barrestin 2 that mediate
their association, a recent study utilised over-expression of indi-
vidual ASK1 domains to demonstrate that only constructs contain-
ing a combination of the kinase and C-terminal domains, but not
either the isolated N- or C-terminal domains of ASK1 alone, could
bind barrestin 2 [8]. These data strongly suggested that the kinase
domain of ASK1 contained the crucial barrestin-binding determi-
nants. The same study, however, reported that both the N- and
C-domains of barrestin 2 could associate independently with
ASK1 [8], though the precise sites of interaction were not eluci-
dated. Here, we show that, in agreement with this work, a GST fu-
sion containing the kinase domain of ASK1 (amino acids 649–946)
bound speciﬁcally to two cognate regions on barrestin 1 and barr-
estin 2 peptide arrays. One region was located in the N-domain,
spanning amino acids 6–35 in barrestin 1 (Fig. 2A, Spots 2 and 3)
and amino acids 6–45 in barrestin 2 (Fig. 2C, Spots 2, 4 and 5)
and one was in the C-domain, spanning barrestin 1 amino acids
376–410 (Fig. 2B, Spots 76, 77 and 78) and barrestin 2 residues
381–405 (Fig. 2D, Spot 77). Puriﬁed GST failed to associate with
any spot within the barrestin1 and barrestin 2 arrays (Fig. 2).
To gain further insight into the amino acids from the barrestin
1 and 2 N-domains that bind speciﬁcally to the ASK1 kinase do-
main, we undertook alanine-scanning analysis of these regions
(Fig. 2E–H). Doing this, however, we saw no obvious single ala-
nine substitution causing loss of binding of the ASK1 kinase do-
main to barrestin 1 (Fig. 2E). Intriguingly, however, several of
the alanine substitutions (V28, H30 and G39) resulted in enhanced
association of the ASK1 kinase domain, compared with the unsub-
stituted control, using this peptide from the barrestin 1 N-domain
(Fig. 2E). Such data further indicate that ASK1 binds this peptide,
is sensitive to changes in its sequence and suggests that multiple
substitutions of amino acids within it may be necessary to com-
promise ASK1 kinase domain binding. Indeed, in this regard, we
determined that a double substitution of D26:D29 ablated binding
in both a peptide array (Fig. 2E) and in vivo when a D26A:D29A
barrestin 1 double mutant was overexpressed in HEK cells
(Fig. 3D). Interestingly, these amino acids have been indicated
in the binding of another kinase (MEK1) to barrestin 1 [17]. The
Fig. 1. Probing a JNK3 peptide library with barrestin 1–GST and barrestin 2–GST. (A) Immobilised peptide spots of overlapping 25-mer peptides each shifted along by ﬁve
amino acids in the entire sequence of JNK3 probed for interaction with either barrestin1–GST, barrestin 2–GST or GST alone. The bar chart represents densitometric analysis of
three independent experiments. (B) Alanine substitution array for the L3–F24 peptide from JNK3 N-terminal was probed with barrestin 1–GST, barrestin 2–GST or GST alone.
A19 was substituted with an aspartate residue.
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terminal was also undertaken (Fig. 2H). These results supported
the notion that the ASK1-binding sites are conserved in the N-ter-
minal regions of both barrestin 1 and 2, as single or double sub-
stitutions of cognate aspartate residues (D26A:D29A) ablated ASK1
binding (Fig. 2H).
In order to probe residues within the C-domain of barrestin 1
and barrestin 2 that mediate ASK1 kinase domain docking, we per-
formed alanine-scanning mutagenesis of the cognate portions of
barrestin 1 and barrestin 2 (Fig. 2F and G). In doing so, we found
that alanine substitution for single residues within the regions
spanning F387-R394 of barrestin 1 and F388–R395 of barrestin 2, or
aspartate substitution of A391 and A392, respectively, ablated barr-
estin interaction with ASK1 kinase domain. These results suggest
that the C-terminal docking site for ASK1 is conserved between
barrestin 1 and barrestin 2.
3.3. Full length MKK4 binds directly to an acidic cluster in barrestin 1
and barrestin 2 N-domain
Recent investigations into scaffolding of the JNK3 cascade by
the barrestin family of proteins have resulted in conﬂicting opin-
ions on how MKK4 is recruited to the complex. One group
postulated that MKK4 has the ability to bind directly to both the
N- and C-domains of all barrestin isoforms [8] while, in contrast,
others postulated that MKK4 might be recruited indirectly via its
association to JNK3 [7,11]. To explore this further, we probed for
a direct interaction using immobilised barrestin 1 and barrestin 2
peptide libraries challenged with puriﬁed MKK4–GST (Fig. 3).
Doing this we readily identiﬁed positive interactions for MKK4
binding to barrestin 1 and barrestin 2 peptides in the region of ami-
no acids 56–90 (Fig. 3A and B, Spots 13, 14 and 15). The positive
interactions were speciﬁc for MKK4 as no such positive interac-
tions were evident when the same peptide library was probed with
puriﬁed GST (Fig. 3). These results suggest the occurrence of a
robust and direct association between MKK4 and the barrestin 1and 2 N-domain. No binding of MKK4 was detected to peptides
representing the C-domain of barrestin 1 or barrestin 2 (results
not shown).
In order to gain more information about the residues that are
important for the association of MKK4 to barrestins, we screened
a family of alanine substitution peptides derived from the 25-
mer parent peptide (barrestin 1: Spot 13) whose sequence re-
ﬂected the region from F61–Q85. A reduced interaction was noted
for individual alanine substitutions of any of E66, D67, D69, K77
and D78 (Fig. 3C) while the triple E66, D67, D69 substitution, each
to alanine, essentially ablated MKK4–GST interaction (Fig. 3C). In
contrast, a paired substitution of alanines for R62, R65 failed to af-
fect MKK4–GST binding (Fig. 3C).
4. Discussion
The maintenance of signalling speciﬁcity and efﬁciency within
MAPK cascades often depends on molecular interaction of signal-
ling intermediates mediated by scaffold proteins [1]. In the case
of the JNK MAPK cascade, a number of different types of scaffold
have been identiﬁed including the JIP family of scaffolds [20] and
the multi-function adaptor proteins, the barrestins [21]. Function-
ally, barrestin 2 acts as a platform in the promotion of robust phos-
phorylation and activation of JNK to enable efﬁcient downstream
signalling in response to stimulation by either G-protein coupled
receptor pathways or through growth factor receptors with intrin-
sic tyrosine kinase activity [6–8,11]. Association with barrestin also
profoundly inﬂuences the cellular location of JNK3, removing this
kinase from the nucleus to the cytoplasm [7,11,22,23] where it
can phosphorylate a range of target proteins. Other functions of
the JNK pathway modulated by sequestration to barrestin include
promotion of JNK dephosphorylation by the MAPK phosphatase,
MKP7 [24] and the ubiquitination of ASK1 by the E3 ligase, CHIP1
[10]. In this study, we used peptide array technology to discover
novel sites of molecular association crucial to the assembly of
the JNK3 signalling module with barrestin (Fig. 4). Previous work
Fig. 2. Peptide array analysis locates two binding sites for ASK1 on barrestin 1 and barrestin 2. Full length barrestin 1 and barrestin 2 peptide arrays consisting of spots of
overlapping 25-mer peptides each shifted along by ﬁve amino acids were probed with the kinase domain of ASK1–GST and GST alone. (A) Positive interaction between ASK1–
GST and the N-domain of barrestin 1 was detected in spots covering amino acids, T6–D35. (B) Interaction between ASK1–GST and the C-domain of barrestin 1 was detected in
spots spanning amino acids L376–T410. (C) Positive interaction between ASK1–GST and the N-domain of barrestin 2 was detected in spots covering amino acids, T6–D45. (D)
Interaction between ASK1–GST and the C-domain of barrestin 2 was detected in a spot spanning amino acids A381–D405. (E) Alanine-scanning substitution array of barrestin 1
K17–G39 peptide sequence together with indicated double substitutions. (F) Alanine-scanning substitution array of barrestin1 F387–S411 peptide sequence together with
indicated double and quadruple substitutions. A391 was mutated to D391. (G) Alanine-scanning substitution array of barrestin 2 V387–D405 peptide sequence together with
indicated double substitutions. A392 was mutated to D392. (H) Alanine-scanning substitution array of barrestin 2 L19–L32 peptide sequence together with indicated double
substitutions.
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Fig. 3. MKK4 binds a putative CD domain in the N-domain of barrestin 1 and barrestin 2. Full length barrestin 1 and barrestin 2 peptide arrays consisting of spots of
overlapping 25-mer peptides each shifted along by ﬁve amino acids were probed with full length MKK4–GST and GST alone. (A) A positive interaction was detected between
MKK4–GST and spots on a barrestin 2 array corresponding to amino acids A61–P95 (Spots 13, 14 and 15). (B) A positive interaction was detected between MKK4–GST and spots
on a barrestin 1 array corresponding to amino acids F61–K95 (Spots 13, 14 and 15). (C) Alanine-scanning substitution array of barrestin 1 F61–Q85 peptide sequence together
with indicated double/triple substitutions. A82 was mutated to D82. (D) Immunoprecipitates of wild-type FLAG-barrestin 1 and D26:D29 FLAG-barrestin 1 were probed for the
association of endogenous ASK1.
Fig. 4. A structural model showing association sites on barrestin for ASK1 and MKK4. The interaction sites for the JNK kinase cascade module are shown mapped onto the
crystal structure of bovine barrestin 1 in its basal state conformation (PDB: 1ZSH) [36]. (Left) The barrestin basal conformation is shown with the C-terminal tail sequence
(clathrin-binding region) folded across the N-domain. In this state both the DVFD sequence (cyan) and (AP-2)-binding sequence (magenta) are expected to be inaccessible for
ASK1 binding. (Right) Unlatching of the C-ter tail sequence allows ASK1 to engage both the (AP-2)-binding region and the DFVD sequence. This is likely to occur with further
interdomain conformational reorganisation (not shown), since the salt bridge of D26 to the arrestin phosphate sensor (R169) in the ‘polar core’ will likely be disrupted upon
kinase binding to D26. The magenta helix shows the structure assumed by the (AP-2)-binding sequence upon binding to the AP-2 b-appendage (PDB: 2IV8) [32]. Conceivably a
similar helical secondary structure might be adopted upon unlatching from the arrestin N-domain and binding to ASK1. The arrestin topology is such that simultaneous
scaffolding contacts from the clathrin-binding region and the DFVD sequence to ASK1 should be feasible. Residues implicated on MKK4 scaffolding are highlighted (green). A
previously identiﬁed locus for JNK3 binding on barrestin 2 is also marked [6].
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(D-site) in the C-terminal of barrestin 2 [6] and it is known that
the short, conserved, basic peptide motifs within D-sites bind to
acidic grooves on MAPK interacting proteins known as commondocking (CD) sites [25]. Contentiously, it has been postulated that
the site of barrestin association on JNK3 is in the N-terminal do-
main of the kinase outside of an area containing an obvious CD site
[8,11]. However, our extensive alanine-scanning analysis (Fig. 1B)
X. Li et al. / FEBS Letters 583 (2009) 3310–3316 3315supports such a contention, by not only clearly deﬁning a barres-
tin-binding site within this location, but also in showing that the
important residues for binding are clearly distinct from a CD motif.
This supports the suggestion [8,11] that JNK3 can interact with the
barrestin protein scaffold through a CD motif-independent binding
site.
Previous work on the JNK/barrestin signalling complex has at-
tempted to identify the molecular determinants that link barrestin
to JNK, ASK1 and MKK4 [6–8,11]. However, no information exists
on the sites on barrestin that accept ASK1 and MKK4. In this study,
we have identiﬁed two cognate regions on barrestin 1 and barrestin
2 that mediate ASK1 binding (Fig. 2) and one cognate site on both
barrestins that facilitates MKK4 binding (Fig. 3). MKK4 is known to
dock to other proteins via its positively charged N-terminal D-site
[26] and the negatively charged E66D67xD69 motif on barrestin 1,
which accepts MKK4, strongly resembles a complementary CD
domain identiﬁed speciﬁcally for the JNK pathway, namely DxxExE
[25]. These residues together with K77 and D78, which were also
implicated in the interaction, are fully conserved between barrestin
1 and barrestin 2 and prominently surface-exposed in the structure
along one edge of the barrestin N-domain b-strand ‘‘sandwich” and
an adjacent loop (Fig. 4). The importance of short docking motifs in
the assembly of MAPK-docking modules has been recognised for
some time [25,27]. However, it is now appreciated thatMAPK,MAP-
KK and MAPKKK can also recognise other targets and scaffold pro-
teins using the same motifs in order to facilitate important
biological outcomes [27]. For example, we have shown recently that
MEK1 can dock to barrestin 1 via a CD domain located within the
N-domain of barrestin 1, thereby inﬂuencing phosphorylation of
barrestin1 by ERK and its subsequent internalisation [17]. Interest-
ingly, the same CD domain (DFVD) on both barrestin 1 and barrestin
2 appears to dock ASK1 (Figs. 2 and 4). This is in agreement with
recent studies, which suggest that although short motif docking of
cognate kinases within speciﬁc MAPK cascades is generally pre-
ferred over non-cognate interactions, the selectivity of certain
MKK docking sites is limited [27]. However, in the case of the
ASK1, additional interaction is provided by engagement of the scaf-
fold’s C-terminal sequence (Fig. 2B, D, F, and G). In the basal arrestin
conformation (Fig. 4), the C-terminal tail sequence folds across the
protein’s N-domain, and in this conﬁguration the two aspartates of
the N-domain DFVD motif are not accessible as a binding interface.
Their accessibility can only be achieved by a conformational change
in the arrestin structure that involves unlatching of the C-terminal
tail sequence from the N-domain. Such structural changes are
known to occur in the binding of arrestins to activated G-protein
coupled receptors [28,29]. Interestingly, the C-terminal sequence
that we identify here as an ASK1-binding site in both barrestin 1
and barrestin 2, is a well-established clathrin adaptor (AP-2)-bind-
ing site that plays a role in key scaffolded receptor internalisation
processes [30,31]. The crystal structure of the isolated sequence
shows that it adopts an a-helical secondary structure in complex
with the clathrin adaptor AP-2 b-appendage (PDB: 2IV8 [32]). It is
possible that in binding to ASK1 the arrestin clathrin adaptor (AP-
2)-binding sequence also assumes a helical organisation (Fig. 4).
The identiﬁcation of both the DFVD sequence and the clathrin-bind-
ingboxasASK1 interactionsites in thepeptidearray studies ishighly
signiﬁcant in that the samestructural reorganisationof theprotein is
required to free both loci as scaffold contact points. There has been
considerable discussion in the literature concerning the oligomeric
status of arrestins in their various scaffolding roles [33,34]. Whilst
we cannot eliminate the possibility that the barrestins associate as
homo- or heterodimers in their assembly of the JNK kinase cascade,
potentially binding ASK1 between the N-terminus of one barrestin
molecule and the C-terminus of a second, the spatial proximity of
the barrestin clathrin adaptor (AP-2)-binding site to the N-domain
DFVD sequence would, feasibly, allow a single barrestin moleculeto scaffold ASK1 using both loci simultaneously (Fig. 4). Moreover,
our identiﬁcation of spatially well-separated loci, common to both
barrestin 1 and barrestin 2, which mediate association of MKK4
and ASK1 indicates that, at least in principle, both of these kinases
might be accommodated simultaneously on a single barrestinmole-
cule. Clearly involvement of the barrestin clathrin adaptor-binding
site in the association with ASK1 might imply mutual exclusivity
in the binding of this kinase and AP-2, with signiﬁcant implications
for internalisation pathways involving the latter. We have not veri-
ﬁed this relationship in the present study, however.
In addition to identifying residues whose mutation compro-
mises ASK1 binding, we have also highlighted a number of in-
stances where Ala mutations in the peptide arrays appear to
enhance ASK1 binding. In the case of the array peptides, which
may differ somewhat to the corresponding regions of the intact pro-
tein in their conformational properties, these mutations may exert
their effects by reducing unfavourable steric or other interactions.
Such interactions need not necessarily be present in the intact pro-
teins, and we have not transferred these mutations into the full
length barrestins to determine whether their enhancing effect is
preserved there. Given the profound barrestin conformational
change inferred upon ASK1 binding, both in terms of tertiary and
local structure, the enhancing effect of these mutations in the array
peptides might also potentially be mediated indirectly by modula-
tion of the conformational properties of the peptide.
The targeting of JNK MAPK for the development of novel thera-
peutics is underway [35] and displacement of MAPK modules from
substrates and scaffolding proteins offers an alternative path to
traditional active site-directed inhibitors. Here we have shown that
approaches using novel scanning peptide array technology may
prove to be a powerful technique to identify potentially important
molecular determinants that may facilitate protein–protein inter-
action interfaces.
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